Could a probiotic gummy help kids with allergies?
NCT ID NCT06885632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a probiotic gummy containing Weizmannia coagulans BC99 can reduce symptoms of allergic rhinitis (hay fever) in children aged 4 to 14. Over 8 weeks, half the children receive the probiotic gummy and half receive a placebo. Researchers track changes in nasal symptoms, immune markers, and gut metabolism to see if the probiotic offers relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Weizmannia coagulans BC99 probiotic gummy
- What this could lead to
- If it works, this could offer a simple, non-drug way to reduce allergy symptoms like sneezing and runny nose in children.
- What could go wrong
- This is a small, early-stage trial with only 52 children, so results may not apply to everyone. The effect may be modest or no better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
52 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Aug 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 14 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1) voluntary participation with written informed consent obtained prior to study enrollment; (2) ability to comply with the study procedures in accordance with the trial protocol; (3) age between 4 and 14 years, inclusive; (4) meeting the diagnostic criteria for AR as outlined in the Guidelines for the Diagnosis and Treatment of Pediatric AR (2022 Revised Edition); (5) presence of at least two of the following symptoms: sneezing, watery rhinorrhea, nasal itching, or nasal congestion, with a total daily symptom duration exceeding one hour, either continuously or cumulatively, and potentially accompanied by ocular manifestations such as ocular itching, tearing, or conjunctival hyperemia; (6) clinical signs including pale and edematous nasal mucosa, with or without watery nasal discharge. Exclusion Criteria: 1. use of medications affecting intestinal flora (e.g., antibacterial drugs, microecological agents, intestinal mucosa protectants, Chinese patent medicines) for more than one continuous week within one month prior to screening; 2. patients with pulmonary tuberculosis; 3. patients with allergic asthma; 4. patients with nasal polyps or severe nasal septum deviation; 5. patients with severe systemic diseases or malignant tumors; 6. patients with congenital genetic diseases or congenital immune deficiency diseases; 7. patients who have regularly used probiotics or prebiotics within 6 months prior to screening; 8. patients with severe digestive tract diseases (including severe diarrhea, inflammatory bowel disease, etc.); 9. patients with metabolic syndrome symptoms (including obesity, abnormal lipid metabolism, hypertension, diabetes, etc.); 10. patients with sinusitis, otitis media, or respiratory tract infections; 11. patients who are allergic to the components of the probiotics used in this trial; 12. patients who have stopped taking the test sample or have taken other drugs midway, making it impossible to determine efficacy or having incomplete data; 13. patients whose recent use of substances with functions similar to the test sample could interfere with the accurate judgment of the trial results; 14. subjects who are unable to participate in the trial due to their own reasons; (15) other subjects deemed ineligible for participation by the researchers.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Children with allergic rhinitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The School of Food and Bioengineering, Henan University of Science and Technolog
Luoyang, Henan, 471000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.